Effect of prophylactic topical hypotensive medications in reducing the incidence of postoperative ocular hypertension after phacoemulsification in dogs.
OBJECTIVE
To determine whether topical hypotensive medications prevent postoperative ocular hypertension (POH) after phacoemulsification.


METHODS
52 client-owned dogs (88 eyes).


METHODS
Diabetic and nondiabetic dogs having undergone phacoemulsification were included in this retrospective study. The control group received no ocular hypotensive medications. The treatment groups received latanoprost, dorzolamide, or dorzolamide/timolol, beginning immediately after surgery, for 2-week duration. IOPs were obtained at initial examination followed by 4 h, 24 h, 7 days, and 14 days postoperatively. POH was defined as an IOP above 20 mmHg (POH20) or 25 mmHg (POH25).


RESULTS
POH20 occurred in 33 of 87 eyes (37.93%), including 11 of 21 eyes (52.38%) in the control group, three of 23 eyes (13.04%) in the latanoprost group, eight of 15 eyes (53.33%) in the dorzolamide group, and 11 of 28 eyes (39.29%) in the dorzolamide/timolol group. Active treatment groups were compared to the control group, and the overall group effect was not significant (P = 0.11). POH25 occurred in 22 of 86 eyes (25.58%), including seven of 21 eyes (33.33%) in the control group, two of 23 eyes (8.70%) in the latanoprost group, five of 15 eyes (33.33%) in the dorzolamide group, and eight of 27 eyes (29.63%) in the dorzolamide/timolol group. Active treatment groups were compared to the control group, and the overall group effect was not significant (P = 0.31). Intraoperative use of intracameral tissue plasminogen activator significantly decreased the chances of POH25 (P = 0.0063).


CONCLUSIONS
The latanoprost group had a substantially lower percentage of POH 20 and POH25 compared to the control and other active treatment groups, although statistical significance was not achieved. Intraoperative intracameral tissue plasminogen activator decreased the incidence of POH25.
Eye Care for Animals, 12419 Metric Blvd, Austin, TX, 78758, USA.
D Dustin
DD
Dees
South Texas Veterinary Ophthalmology, 503 E. Sonterra Blvd, Suite 102, San Antonio, TX, 78258, USA.
Kate J
KJ
Spahn
South Texas Veterinary Ophthalmology, 503 E. Sonterra Blvd, Suite 102, San Antonio, TX, 78258, USA.
Lynsey Smith
LS
Wagner
South Texas Veterinary Ophthalmology, 503 E. Sonterra Blvd, Suite 102, San Antonio, TX, 78258, USA.
Andrew
A
Greller
Eye Care for Animals, 12419 Metric Blvd, Austin, TX, 78758, USA.
Danielle
D
Paglia
Eye Care for Animals, 165 Fort Evans Road NE, Suite 107, Leesburg, VA, 20176, USA.
Micki D
MD
Armour
University of Missouri Health System, One Hospital Drive, Columbia, MO, 65212, USA.
Richard
R
Madsen
D000287:Administration, Topical; D000818:Animals; D004283:Dog Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D009798:Ocular Hypertension / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D018918:Phacoemulsification / Q000009:adverse effects / Q000662:veterinary*; D011183:Postoperative Complications / Q000517:prevention & control / Q000662:veterinary*; D065129:Pre-Exposure Prophylaxis; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage; D013876:Thiophenes / Q000008:administration & dosage; D013999:Timolol / Q000008:administration & dosage
D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D013449:Sulfonamides; D013876:Thiophenes; D000077338:Latanoprost; D013999:Timolol; C062765:dorzolamide
canine; cataract; glaucoma; phacoemulsification; postoperative ocular hypertension